A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials